Glutathione S-transferase P1-1 as a target for mesothelioma treatment

Cancer Science

Volumn 104, Issue 2, 2013, Pages 223-230

  De Luca, Anastasia ^a   Pellizzari Tregno, Francesca ^a   Sau, Andrea ^a   Pastore, Anna ^b   Palumbo, Camilla ^a   Alama, Angela ^c   Cicconi, Rosella ^a   Federici, Giorgio ^b   Caccuri, Anna M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CISPLATIN; ENZYME INHIBITOR; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE P1 1; NBDHEX; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE 4; MCF-7 CELLS; MESOTHELIOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; OXADIAZOLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLEURAL NEOPLASMS;

EID: 84873705803     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12061     Document Type: Article

References (53)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.
2. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 2010; 101: 1-6.
3. Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008; 14: 303-9.
4. van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: The standard of care and challenges for future management. Crit Rev Oncol Hematol 2011; 78: 92-111.
5. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 535-9.
6. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.
7. Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest 1998; 113: 61S-5S.
8. Aelony Y. Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage. J Clin Oncol 2006; 24: 4667-8.
9. Fennell DA, Steele JP, Shamash J et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 2007; 109: 93-9.
10. Lazzarini R, Moretti S, Orecchia S, Betta PG, Procopio A, Catalano A. Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. Clin Cancer Res 2008; 14: 5099-107.
11. Maruyama R, Shoji F, Okamoto T et al. Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. Jpn J Clin Oncol 2005; 35: 433-8.
12. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008; 99: 44-50.
13. Chen SE, Pace MB. Malignant pleural mesothelioma. Am J Health Syst Pharm 2012; 69: 377-85.
14. Grosso F, Scagliotti GV. Systemic treatment of malignant pleural mesothelioma. Future Oncol 2012; 8: 293-305.
15. Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008; 9: 171-9.
16. Mott FE. Mesothelioma: a review. Ochsner J 2012; 12: 70-9.
17. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38: 111-21.
18. Shea TC, Kelley SL, Henner WD. Identification of an anionic form of glutathione transferase present in many human tumors and human tumor cell lines. Cancer Res 1988; 48: 527-33.
19. Tew KD, Monks A, Barone L et al. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol 1996; 50: 149-59.
20. Licht T, Fiebig HH, Bross KJ et al. Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 1991; 49: 630-7.
21. Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000; 59(Suppl 4): 1-8; Discussion 37-8.
22. Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008; 7: 3247-55.
23. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007; 251: 1-16.
24. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 1-13.
25. Adler V, Yin Z, Fuchs SY et al. Regulation of JNK signaling by GSTp. EMBO J 1999; 18: 1321-34.
26. De Luca A, Federici L, De Canio M, Stella L, Caccuri AM. New Insights into the Mechanism of JNK1 Inhibition by Glutathione Transferase P1-1. Biochemistry 2012; 51: 7304-12.
27. Yin Z, Ivanov VN, Habelhah H, Tew K, Ronai Z. Glutathione S-transferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases. Cancer Res 2000; 60: 4053-7.
28. Wu Y, Fan Y, Xue B et al. Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene 2006; 25: 5787-800.
29. Ricci G, De Maria F, Antonini G et al. 7-Nitro-2, 1, 3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs. J Biol Chem 2005; 280: 26397-405.
30. Turella P, Cerella C, Filomeni G et al. Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res 2005; 65: 3751-61.
31. Ascione A, Cianfriglia M, Dupuis ML et al. The glutathione S-transferase inhibitor 6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells. Cancer Chemother Pharmacol 2009; 64: 419-24.
32. Filomeni G, Turella P, Dupuis ML et al. 6-(7-Nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol Cancer Ther 2008; 7: 371-9.
33. Turella P, Filomeni G, Dupuis ML et al. A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells. 6-(7-Nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells. J Biol Chem 2006; 281: 23725-32.
34. Pasello M, Manara MC, Michelacci F et al. Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal Cell Pathol (Amst) 2011; 34: 131-45.
35. Pasello M, Michelacci F, Scionti I et al. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 2008; 68: 6661-8.
36. Pellizzari Tregno F, Sau A, Pezzola S et al. In vitro and in vivo efficacy of 6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma. Eur J Cancer 2009; 45: 2606-17.
37. Scotlandi K, Remondini D, Castellani G et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 2009; 27: 2209-16.
38. Sau A, Filomeni G, Pezzola S et al. Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Mol BioSyst 2012; 8: 994-1006.
39. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
40. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.
41. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10: 7994-8004.
42. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
43. Pastore A, Massoud R, Motti C et al. Fully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione, cysteamine, and 2-mercaptopropionylglycine in plasma and urine. Clin Chem 1998; 44: 825-32.
44. Jhaveri MS, Morrow CS. Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells. Gene 1998; 210: 1-7.
45. Huang Z, Pinto JT, Deng H, Richie JP Jr. Inhibition of caspase-3 activity and activation by protein glutathionylation. Biochem Pharmacol 2008; 75: 2234-44.
46. Shukla A, Bosenberg MW, MacPherson MB et al. Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol 2009; 175: 2197-206.
47. Muscarella DE, Bloom SE. The contribution of c-Jun N-terminal kinase activation and subsequent Bcl-2 phosphorylation to apoptosis induction in human B-cells is dependent on the mode of action of specific stresses. Toxicol Appl Pharmacol 2008; 228: 93-104.
48. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-78.
49. Poommipanit PB, Chen B, Oltvai ZN. Interleukin-3 induces the phosphorylation of a distinct fraction of bcl-2. J Biol Chem 1999; 274: 1033-9.
50. Zipper LM, Mulcahy RT. Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes. Biochem Biophys Res Commun 2000; 278: 484-92.
51. Lee JM, Johnson JA. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 2004; 37: 139-43.
52. Brozovic A, Ambriovic-Ristov A, Osmak M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol 2010; 40: 347-59.
53. Tentori L, Dorio AS, Mazzon E et al. The glutathione transferase inhibitor 6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. Eur J Cancer 2011; 47: 1219-30.